Clinical Development Cosmetics Dermatology 
The Pharma Data
MARCH 4, 2021
associate professor of Dermatology at Yale School of Medicine. AA is the second potential treatment indication in dermatology for baricitinib after AD. “For patients who suffer from alopecia areata, it is not a cosmetic condition, it is a devastating autoimmune disease that can have significant psychological effects.
XTalks
JUNE 17, 2024
RELATED: Innovations and Clinical Trial Diversity in Medical Aesthetics: Insights from Dr. Stephanie Manson Brown, VP & Head of Clinical Development at Allergan Aesthetics – Xtalks Life Science Podcast Ep. 134 How Does Letybo Work? Letybo is classified as an acetylcholine release inhibitor and neuromuscular blocking agent.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
AUGUST 2, 2023
2) Botox Therapeutic/Cosmetic Botox, or botulinum neurotoxin, is a neurotoxic protein produced by the Clostridium botulinum bacteria. In partnership with Seagen, Sanofi will design, develop and commercialize ADCs for three cancer targets using Sanofi’s proprietary monoclonal antibody technology and Seagen’s proprietary ADC technology.
The Pharma Data
NOVEMBER 4, 2020
(TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.
The Pharma Data
NOVEMBER 4, 2020
Initial data from an ongoing long-term, open label extension study with CTP-543 were presented in the late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 29, 2020. Published Findings on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology.
Expert insights. Personalized for you.
52 
Let's personalize your content